en سلول های بنیادی و پزشکی بازساختی Stem Cell and Regenerative Medicine مقاله مروری Review Article <span style="font-size:11pt"><span new="" roman="" style="font-family:" times=""><span style="font-size:10.0pt">Stroke, is accounting for more than 34% of total healthcare spending globally. Ischemic stroke (IS) accounts for 62.4% of incident stroke cases. IS-related direct medical expenditures place a considerable burden on healthcare system. The burden is more prominent in developing countries where limitations in insurance coverage is a big concern. It would be less challenging in developed countries, where costs are covered by third parties.</span></span></span><br> <span style="font-size:11pt"><span new="" roman="" style="font-family:" times=""><span style="font-size:10.0pt">After introduction of advanced therapeutic medicinal products (ATMPs), a new line of treatments is proposed. Although the high prices of these treatments may cause financial concerns, they have encouraged scientists and provided acceptable results in a way that makes investment in this area reasonable for health experts. All ATMP-based therapies used in clinical trials for the treatment of IS are stem-cell-based or stem-cell-derivatives. The cost of stem-cell-based therapies are considerable like other alternative medical settings, e.g., thrombolysis and thrombectomy. However, the considerable recovery after prescription of ATMPs is expected to be cost-effective. Furthermore, various gene therapy approaches for the treatment of IS have been proposed. However, none has been qualified for clinical studies yet. If such a procedure is introduced in near future, it does not necessarily guarantee that these innovative treatments would be offered to the patients.&nbsp;&nbsp; Application of ATMPs have many challenges particularly in developing countries. This is primarily related to exorbitant expenditures. Despite these challenges, the insurance systems in developed-countries supports stem-cell therapies as novel treatments. Significant improvements in the insurance systems of both developing and developed countries are necessary.</span></span></span><br> &nbsp; Advanced therapeutic medicinal products (ATMPs), Ischemic stroke, Insurance systems, Developing countries 38 46 http://modernmedlab.com/browse.php?a_code=A-10-73-15&slc_lang=en&sid=1 Shahriar Ghashghaei sh.gh2035@gmail.com 10031947532846001999 10031947532846001999 No Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran Maryam Alsadat Mousavi maryamalsadatmousavi@yahoo.com 10031947532846002000 10031947532846002000 No Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran Shahedeh Karimi karimi58shah@gmail.com 10031947532846002001 10031947532846002001 No Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran Seyed Sam Nadali Pour samndpr@gmail.com 10031947532846002002 10031947532846002002 No Faculty of Economics and Social Sciences, Shahid Chamran University, Ahwaz, Iran Seyed Massood Nabavi seyedmassoodnabavi@gmail.com 10031947532846002003 10031947532846002003 No Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran Massoud Vosough masvos@royanistitiue.org 10031947532846002004 10031947532846002004 Yes Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran